Project Grant F32DA061631
Award Date
2/1/25
Completion Date
8/31/27
Dollars Obligated
$148K
Federal Agency
National Institute on Drug Abuse
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This $284,040 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to conduct integrated single-cell and spatial mapping of the habenula circuitry to identify projection-specific molecular pathways associated with opioid exposure. The Lieber Institute for Brain Development in Baltimore, MD will lead this research effort from September 1, 2024 to August 31, 2026. The project will generate a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $234,000.00 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids such as fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, as well as to longitudinally measure and...
The National Institute on Drug Abuse (NIDA) awarded a $154,568 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis. The grant, titled "Investigating the Role of Dorsal Raphe Nucleus Enkephalin Neurons in Motivational and Affective Behaviors During Chronic Pain", aims to determine the contribution of endogenous opioids in the dorsal raphe nucleus to motivational and affective dysregulation during chronic pain. The...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $759,339 to The Trustees of the University of Pennsylvania to conduct research on the role of central amylin receptors in opioid-mediated behaviors. The key objectives are to: Comprehensively define the functional roles of cell type-specific ventral tegmental area (VTA) and nucleus accumbens (NAc) amylin receptors in opioid taking and seeking behaviors...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,411,145 to Rowan University from September 30, 2024 to July 31, 2029. The project aims to unravel the neurobiological mechanisms by which the GPR83 receptor and its endogenous ligand PEN interact with the mu-opioid receptor (MOR) in the periaqueductal gray region of the brain. This research seeks to determine if targeting the GPR83 pathway can...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...